Biogen Inc BIIB:NASDAQ

Last Price$234.88Cboe Real-Time Last Sale as of 1:15PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.86(0.36%)
Bid (Size)$234.34 (22)
Ask (Size)$234.68 (1)
Day Low / High$234.34 - 239.58
Volume597.0 K
 

View Biotechnology IndustryPeer Comparison as of 12/01/2021

 

Biogen Inc ( NASDAQ )

Price: $234.88
Change: -0.86 (0.36%)
Volume: 597.0 K
1:15PM ET 12/01/2021
 
 

Seagen Inc ( NASDAQ )

Price: $160.08
Change: +0.08 (0.05%)
Volume: 853.5 K
1:17PM ET 12/01/2021
 
 

Agilent Technologies Inc ( NYSE )

Price: $150.96
Change: +0.06 (0.04%)
Volume: 807.9 K
1:17PM ET 12/01/2021
 
 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $184.23
Change: +0.43 (0.23%)
Volume: 169.2 K
1:08PM ET 12/01/2021
 
 

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $201.75
Change: +14.81 (7.92%)
Volume: 3.6 M
1:16PM ET 12/01/2021
 

Read more news Recent News

Market Chatter: Biogen Loses Appeals Court Bid to Revive Multiple Sclerosis Drug Patent
2:02PM ET 11/30/2021 MT Newswires

Biogen (BIIB) lost a US appeals court bid to protect its patent for multiple sclerosis drug Tecfidera, Bloomberg reported Tuesday. The US Court of Appeals...

Market Chatter: Biogen's Alzheimer's Drug Reportedly Caused Brain Swelling in Over One-Third of Patients, Study Shows
3:46PM ET 11/22/2021 MT Newswires

Biogen's (BIIB) Alzheimer's drug, Aduhelm, resulted in brain swelling in 35% of patients, Bloomberg News reported Monday, citing company researchers. A...

RBC Cuts Price Target on Biogen to $277 From $295 Amid Alzheimer's Updates, Maintains Sector Perform Rating
8:37AM ET 11/19/2021 MT Newswires

Biogen (BIIB) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $209 to $502. (MT...

--BMO Capital Initiates Coverage of Biogen With Outperform Rating, $315 Price Target
4:29PM ET 11/18/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Alzheimer's Update: More Disarray
8:00AM ET 12/01/2021 Seeking Alpha

My 29-Stock $410k November Portfolio Is Ready For The Santa Claus Rally
7:36AM ET 12/01/2021 Seeking Alpha

Praxis Precision Medicines: Genetic Medicines For Neurological Disease
11:08AM ET 11/23/2021 Seeking Alpha

Cortexyme: A Challenging Path Forward
12:06AM ET 11/17/2021 Seeking Alpha

Company Profile

Business DescriptionBiogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. View company web site for more details
Address225 Binney Street
Cambridge, Massachusetts 02142
Phone+1.617.679.2000
Number of Employees7,800
Recent SEC Filing11/30/20214
Chief Executive Officer & DirectorMichel Vounatsos
EVP-Pharmaceutical Operations & TechnologyAlphonse Galdes
Chief Financial Officer & Executive Vice PresidentMichael R. McDonnell
Head-Research & DevelopmentAlfred W. Sandrock

Company Highlights

Price Open$236.98
Previous Close$235.74
52 Week Range$228.68 - 468.55
Market Capitalization$34.5 B
Shares Outstanding146.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings23.77
Earnings per Share$13.56
Beta vs. S&P 500N/A
Revenue$12.1 B
Net Profit Margin17.77%
Return on Equity14.53%

Analyst Ratings as of 11/17/2021

Buy
15
Overweight
2
Hold
14
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset